Literature DB >> 12847670

Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions.

David T Felson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12847670     DOI： 10.1002/art.11087

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  3 in total

Review 1.  Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Matt Stevenson; Rachel Archer; John W Stevens; Edward Goka; Mark Clowes; David L Scott; Adam Young
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

Review 2.  Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Lesley Uttley; Iñigo Bermejo; Shijie Ren; Marrissa Martyn-St James; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 3.  Outcome measures in inflammatory rheumatic diseases.

Authors:  Jaap Fransen; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.